AngioDynamics to Report Fiscal Second Quarter 2009 Financial Results and Hold Conference Call on January 6, 2009QUEENSBURY, N.Y.--(BUSINESS WIRE)--
Dec. 16, 2008--
AngioDynamics, Inc. (NASDAQ:ANGO), a leading provider of
innovative medical devices used by interventional radiologists,
nephrologists and surgeons for the minimally invasive treatment of
cancer and peripheral vascular disease, announced today that it will
report its second fiscal quarter financial results on
Tuesday, January
6, 2009 after the close of the financial markets.
Eamonn P. Hobbs, president and chief executive officer, and Joseph
Gersuk, executive vice president and CFO, will host an investment
community conference call beginning at 4:30 p.m. Eastern time on January
6 to discuss these results and to answer questions.
To participate in the live call by telephone, please dial (800) 218-0713
from the U.S., or for international callers, please dial +1 (303)
262-2130.
Those interested in listening to the conference call live via the
Internet may do so by visiting the Investor Relations section of
AngioDynamics' website at http://investor.angiodynamics.com.
To listen to the live call, please go to the website 15 minutes prior to
its start to register, download, and install the necessary audio
software.
A replay will be available on the website. A telephone replay will be
available from 6:30 p.m. Eastern time on January 6, 2009 through 11:59
p.m. Eastern time on January 13 by dialing (800) 405-2236 (domestic) or
+1 (303) 590-3000 (international) and entering the passcode: 11123338#.
About AngioDynamics
AngioDynamics, Inc. is a leading provider of innovative medical devices
used by interventional radiologists, nephrologists and surgeons for the
minimally invasive treatment of cancer and peripheral vascular disease.
The Company's diverse product line includes market-leading
radiofrequency ablation and irreversible electroporation resection
systems, vascular access products, angiographic products and
accessories, dialysis products, angioplasty products, drainage products,
thrombolytic products, embolization products and venous products. More
information is available at www.angiodynamics.com.
CONTACT: AngioDynamics, Inc.
D. Joseph Gersuk, CFO, 800-772-6446 ext. 1608
jgersuk@AngioDynamics.com
or
EVC Group, Inc.
Doug Sherk, 415-896-6820 (Investor Relations)
dsherk@evcgroup.com
Jenifer Kirtland, 415-896-6820 (Investor Relations)
jkirtland@evcgroup.com
Chris Gale, 646-201-5431 (Media)
cgale@evcgroup.com
Source: AngioDynamics, Inc.
